William Wang

William Wang

Auto-generated profile, based on publicly available information

William Wang

Center for Science, Health, and Society, Case Western Reserve University School of Medicine, Cleveland, Ohio (W.W., N.A.B.)

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2024 in Annals of Internal Medicine
Verified
Journal Article
Closed access
WWWilliam Wang
William Wang
NVNora D Volkow
Nora D Volkow
Nathan BergerNathan Berger
Nathan Berger
PDPamela B. Davis
Pamela B. Davis
DKDavid . Kaelber
David . Kaelber
RXRong Xu
Rong Xu
Reports of reduced desire to smoke in patients treated with semaglutide, a glucagon-like peptide receptor agonist (GLP-1RA) medication for type 2 diabetes mellitus (T2DM) and obesity, have raised interest about its potential benefit for tobacco use disorders (TUDs). To examine the association of semaglutide with TUD-related health care measures in patients with comorbid T2DM and TUD. Emulation target trial based on a nationwide population-based database of patient electronic health records. United States, 1 December 2017 to 31 March 2023. Seven target trials were emulated among eligible patients with comorbid T2DM and TUD by comparing the new use of semaglutide versus 7 other antidiabetes medications (insulins, metformin, dipeptidyl-peptidase-4 inhibitors, sodium-glucose cotransporter-2 inhibitors, sulfonylureas, thiazolidinediones, and other GLP-1RAs). The TUD-related health care measures (medical encounter for diagnosis of TUD, smoking cessation medication prescriptions, and smoking cessation counseling) that occurred within a 12-month follow-up were examined using Cox proportional hazards and Kaplan-Meier survival analyses. The study compared 222 942 new users of antidiabetes medications including 5967 of semaglutide. Semaglutide was associated with a significantly lower risk for medical encounters for TUD diagnosis compared with other antidiabetes medications, and was strongest compared with insulins (hazard ratio [HR], 0.68 [95% CI, 0.63 to 0.74]) and weakest but statistically significant compared with other GLP-1RAs (HR, 0.88 [CI, 0.81 to 0.96]). Semaglutide was associated with reduced smoking cessation medication prescriptions and counseling. Similar findings were observed in patients with and without a diagnosis of obesity. For most of the group comparisons, the differences occurred within 30 days of prescription initiation. Documentation bias, residual confounding, missing data on current smoking behavior, body mass index, and medication adherence. Semaglutide was associated with lower risks for TUD-related health care measures in patients with comorbid T2DM and TUD compared with other antidiabetes medications including other GLP-1Ras, primarily within 30 days of prescription. These findings suggest the need for clinical trials to evaluate semaglutide's potential for TUD treatment. National Institutes of Health.

30 October 2023 in American Journal of Gastroenterology
Verified
Journal Article
Open access
WWWilliam Jiaen Wang
William Jiaen Wang
DFDaphne Foong
Daphne Foong
SCStefan Calder
Stefan Calder
Gabriel SchambergGabriel Schamberg
Gabriel Schamberg
CVChris Varghese
Chris Varghese
GOGreg O'Grady
Greg O'Grady
INTRODUCTION: Gastric emptying testing (GET) assesses gastric motility, however, is nonspecific and insensitive for neuromuscular disorders. Gastric Alimetry (GA) is a new medical device combining noninvasive gastric electrophysiological mapping and validated symptom profiling. This study assessed patient-specific phenotyping using GA compared with GET. METHODS: Patients with chronic gastroduodenal symptoms underwent simultaneous GET and GA, comprising a 30-minute baseline, 99mTC-labelled egg meal, and 4-hour postprandial recording. Results were referenced to normative ranges. Symptoms were profiled in the validated GA App and phenotyped using rule-based criteria based on their relationships to the meal and gastric activity: (i) sensorimotor, (ii) continuous, and (iii) other. RESULTS: Seventy-five patients were assessed, 77% female. Motility abnormality detection rates were as follows: GET 22.7% (14 delayed, 3 rapid), GA spectral analysis 33.3% (14 low rhythm stability/low amplitude, 5 high amplitude, and 6 abnormal frequency), and combined yield 42.7%. In patients with normal spectral analysis, GA symptom phenotypes included sensorimotor 17% (where symptoms strongly paired with gastric amplitude, median r = 0.61), continuous 30%, and other 53%. GA phenotypes showed superior correlations with Gastroparesis Cardinal Symptom Index, Patient Assessment of Upper Gastrointestinal Symptom Severity Index, and anxiety scales, whereas Rome IV Criteria did not correlate with psychometric scores (P > 0.05). Delayed emptying was not predictive of specific GA phenotypes. DISCUSSION: GA improves patient phenotyping in chronic gastroduodenal disorders in the presence and absence of motility abnormalities with increased correlation with symptoms and psychometrics compared with gastric emptying status and Rome IV criteria. These findings have implications for the diagnostic profiling and personalized management of gastroduodenal disorders.

18 June 2023 in Gut
Verified
Conference Paper
Closed access
PDF file
WWWilliam Wang
William Wang
DFDaphne Foong
Daphne Foong
SCStefan Calder
Stefan Calder
Gabriel SchambergGabriel Schamberg
Gabriel Schamberg
CVChris Varghese
Chris Varghese
GOGreg O’grady
Greg O’grady
Background Gastric emptying testing (GET), while useful for evaluating gastric motility, is not specific nor sensitive for neuromuscular disorders. However, Gastric Alimetry® (GA) is a novel medical test that uses gastric mapping and validated symptom profiling. The current study compared the patient-specific phenotyping from GA with GET. Methods Patients with chronic gastroduodenal symptoms completed GET and GA concurrently. Tests included a 30-minute baseline, 99mTC-labelled egg meal and 4-hour postprandial recording. Results were compared to the reference normative ranges. The validated GA App profiled symptoms and subsequently phenotyped them using rule-based criteria into either: 1) Continuous (no correlation between symptoms and meal or gastric activity); 2) Gastric Sensorimotor (correlation between symptoms and meal or gastric activity); 3) or Other, to compare with questionnaires. Results 75 patients with chronic gastroduodenal symptoms were assessed; 77% female, median age 43, median BMI 24.0. Motility abnormality detection rates were 22.7% (GET); 33.3% (GA) with a combined yield 42.7%. All groups showed similar symptom profiles and did not correlate with Rome criteria or health psychology factors (p>0.05). GA symptom phenotypes (figure 1A) were: gastric sensorimotor 17%; continuous 30%; other 53%. Strong correlations between the sensorimotor phenotype and gastric amplitude were observed (median r=0.61 vs r=0.08 and r=0.06 respectively; p=0.0002). The continuous phenotype correlated with depression and anxiety (p0.05). No correlation between GET abnormalities and GA phenotypes was found (figure 1B). Conclusion In patients with chronic gastroduodenal symptoms, GA produced a high yield for motility abnormalities, compared to GET. Additionally, GA found correlations between patient-specific symptom phenotypes and health psychology factors, which were not identified by ROME IV and GET. Together, the results suggest that GA and GET may work in conjunction with each other by assessing different features of gastric functioning. Diagnostic evaluation by GET and GA. A) Overall diagnostic outcomes of GA spectral and symptom phenotyping. B) Sankey plot showing limited concordance between GA spectral or symptom phenotypes with GET abnormalities

6 July 2023 in Gastroenterology
Verified
Journal Article
Closed access
WWWilliam J. Wang
William J. Wang
DFDaphne Foong
Daphne Foong
SCStefan S. Calder
Stefan S. Calder
Gabriel SchambergGabriel Schamberg
Gabriel Schamberg
CVChris Varghese
Chris Varghese
GOGreg O'Grady
Greg O'Grady